BI Asset Management Fondsmaeglerselskab A S Lowers Stake in United Therapeutics Corporation $UTHR

BI Asset Management Fondsmaeglerselskab A S cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 59.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,875 shares of the biotechnology company’s stock after selling 17,188 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in United Therapeutics were worth $5,786,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on UTHR. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, HC Wainwright increased their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total transaction of $4,540,681.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $24,712,246.04. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,323.93. The trade was a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 614,543 shares of company stock worth $346,728,395 in the last 90 days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $549.87 on Monday. The company’s fifty day moving average price is $568.23 and its two-hundred day moving average price is $519.16. The firm has a market capitalization of $23.34 billion, a P/E ratio of 20.30, a P/E/G ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the business earned $6.63 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.